Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial

• Main Authors: Esaú C. João, R. Leavitt Morrison, David E. Shapiro, Nahida Chakhtoura, Maria Isabel S. Gouvèa, Maria de Lourdes B Teixeira, Trevon L. Fuller, Blandina T. Mmbaga, James S. Ngocho, Boniface N. Njau, Avy Violari, Ruth Mathiba, Zaynab Essack, Jose Henrique S. Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Pedro Cahn, Sinart Prommas, Timothy R. Cressey, Kulkanya Chokephaibulkit, Peerawong Werarak, Lauren Laimon, Roslyn Hennessy, Lisa M. Frenkel, Patricia Anthony, Brookie M. Best, George K. Siberry, Mark Mirochnick
• Format: Journal
• Published: 2020
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084203155&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/70663
• Institution: Chiang Mai University

© 2020 Elsevier Ltd Background: Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated d...